|Description||Ciluprevir is used experimentally in the treatment of hepatitis C. It is manufactured by Boehringer Ingelheim Pharma GmbH & Co. kg and developed under the research code of BILN-2061. It is targeted against NS2-3 protease.|
|Synonyms||BILN 2061; BILN-2061; BILN2061; BILN-2061ZW; BILN2061ZW; BILN 2061ZW; Ciluprevir|
VX-222 (VCH-222, Lomibuvir)
VX-222 (VCH-222) is a novel, potent and selective inhibitor of HCV polymerase with IC50 of 0.94-1.2 μM, 15.3-fold less effective for mutant M423T, and 108-fold ...
HZ-1157 is an inhibitor of hepatitis C virus (HCV) nonstructural protein 3/4A (NS3/4A) protease.
Nesbuvir, a novel selective nonstructural protein 5B (NS5B) polymerase inhibitor, acts as candidate for HCV treatment. It was reduced across different isolates.
PSI-6130 is a potent and selective inhibitor of HCV NS5B polymerase. It is metabolized to two pharmacologically active species in primary human hepatocytes.
Dasabuvir is an antiviral drug for the treatment of hepatitis C. It inhibits hepatitis C virus (HCV) non-nucleoside NS5B palm polymerase to suppress RNA replica...
Narlaprevir is a potent, selective, orally bioavailable inhibitor of the hepatitis C virus (HCV) nonstructural protein 3 serine protease that is primarily metab...
Daclatasvir is a highly selective inhibitor of HCV NS5A with EC50 of 9-50 pM, for a broad range of HCV replicon genotypes and the JFH-1 genotype 2a infectious v...
Sofosbuvir is a prodrug that is metabolized to the active antiviral agent 2'-deoxy-2'-α-fluoro-β-C-methyluridine-5'-monophosphate and is currently being investi...